EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Search
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
inauguration_biopharmaceutical_production_facility_vienna
The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Boehringer Ingelheim acquires Global Stem cell Technology
Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Partnership to further develop pet market in China
Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
Partnering with Constantia Flexibles for augmented reality
Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Making-more-health-together-2021
1,200 participants from around the world join virtual convention on November 11-12
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Animal Welfare through environmental sustainability
Producing honey and contributing to environmental sustainability during your work hours.
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
It is about saving lives Alexis Jaliquias feline blood bank
Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America
Interview Dr Mehdi Shahidi
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Zoonotic diseases things you should know
Zoonotic diseases can be transmitted between animals and humans. They are more common than you may think – and they are on the rise. Find out how this affects you.
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
H5N1: Bird flu again. What’s different now?
H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.
Empowering smallholder farmers
The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD
FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.